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ABSTRACT 
Background and aims  
In a 2010 randomized trial (the PANTER trial), a surgical step-up approach for infected necrotizing 
pancreatitis was found to reduce the composite endpoint of death or major complications compared 
with open necrosectomy; 35% of patients were successfully treated with simple catheter drainage 
only. There is concern, however, that minimally invasive treatment increases the need for 
reinterventions for residual peripancreatic necrotic collections and other complications during the long 
term. We therefore performed a long-term follow-up study. 
Methods 
We re-evaluated all the 73 patients (of the 88 patients randomly assigned to groups) who were still 
alive after the index admission, at a mean 86 months (±11 months) follow up. We collected data on all 
clinical and health care resource utilization endpoints through this follow-up period. The primary 
endpoint was death or major complications (the same as for the PANTER trial). We also measured 
exocrine insufficiency, quality of life (using the SF-36 and EQ-5D forms) and Izbicki pain scores. 
Results 
From index admission to long-term follow up, 19 patients (44%) died or had major complications in the 
step-up group compared with 33 patients (73%) in the open-necrosectomy group (P=.005). 
Significantly lower proportions of patients in the step-up group had incisional hernias (23% vs 53%; 
P=.004), pancreatic exocrine insufficiency (29% vs 56%; P=.03), or endocrine insufficiency (40% vs 
64%; P=.05). There were no significant differences between groups in proportions of patients requiring 
additional drainage procedures (11% vs 13%; P=.99) or pancreatic surgery (11% vs 5%; P=.43), or in 
recurrent acute pancreatitis, chronic pancreatitis, Izbicki pain-scores, or medical costs. Quality of life 
increased during follow up without a significant difference between groups. 
Conclusions 
In an analysis of long-term outcomes of trial participants, we found the step-up approach for 
necrotizing pancreatitis to be superior to open necrosectomy, without increased risk of reinterventions. 
 
Keywords 
Pancreas; infected necrosis; minimally invasive, pancreatic surgery 
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Background and aims 
Infected necrotizing pancreatitis typically requires invasive intervention.1,2 Traditionally, primary open 
necrosectomy with extensive debridement and post-operative lavage was the preferred treatment. In 
the last 3 decades, minimally invasive catheter drainage and necrosectomy methods have become 
increasingly popular.3 In 2010, we published the first randomized controlled trial (the PANTER trial) on 
invasive treatment for infected necrotizing pancreatitis.4 We compared primary open necrosectomy 
with a novel surgical step-up approach in 88 patients with necrotizing pancreatitis. The step-up 
approach consisted of primary percutaneous catheter drainage, followed, if necessary, by minimally 
invasive retroperitoneal necrosectomy. The step-up approach aims to provide source control, rather 
than complete removal of the infected necrotic tissue. This decreases the pro-inflammatory response 
induced by surgical trauma, which may prevent further clinical deterioration and may obviate the need 
for necrosectomy. The step-up approach significantly reduced the composite primary endpoint of 
major complications and death (risk ratio 0.57). Also, 35% of patients assigned to the step-up group 
were successfully treated with percutaneous catheter drainage only. The secondary endpoints of 
incisional hernia, new-onset diabetes, use of pancreatic enzymes and total costs at 6 months follow up 
were also reduced in the step-up group.4 International guidelines now advocate a surgical or 
endoscopic step-up approach as standard treatment of infected necrotizing pancreatitis.1,5-8  
The two treatment strategies compared in the PANTER trial differ fundamentally in terms of 
anatomical approach and the extent in which necrotic material is removed. In a third of all patients 
from the step-up approach, only infected fluid was drained from the collection and necrosis was left in 
situ. As a result, patients who initially recovered from their sepsis without necrosectomy may have 
developed symptoms and complications from residual peripancreatic collections with necrosis that 
require percutaneous, endoscopic, or surgical interventions beyond the initial 6 months follow up of 
the trial. Repeated re-admissions and disease burden from other long-term complications such as 
incisional hernias, pancreatic insufficiency, or persisting abdominal pain may also differ between the 
step-up approach and primary open necrosectomy. In general, post-trial follow-up studies of 
randomized trials are regarded to be important to detect long-term differences in safety and efficacy 
outcomes.9 We therefore performed a study, 86 months after the first analysis of the PANTER trial, to 
compare the long-term follow up of the step-up approach with primary open necrosectomy in terms of 
clinical outcomes, healthcare utilization and quality of life. 
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Methods 
Patients and treatment during follow up 
Between November 2005 and October 2008, 88 patients with (suspected or confirmed infected) 
necrotizing pancreatitis were randomly assigned to the step-up approach (n=43) or primary open 
necrosectomy (n=45). In total, 15 patients died during the PANTER trial, 8 patients in the step-up 
group and 7 in the open-necrosectomy group, leaving a total of 73 patients eligible for long-term follow 
up.4 Diagnostics and treatment beyond the initial follow up of 6 months were not defined by protocol of 
the PANTER trial and was performed at the discretion of the treating physician. 
 
Timeline 
Final discharge date of the last admitted patient during the PANTER trial was on January 19, 2009. 
Ethical approval for the current nationwide follow-up study in the original 19 Dutch hospitals 
participating in the PANTER trial was given by the medical ethics committee of the University Medical 
Center Utrecht by the end of October 2013. After primary contact, follow-up visits of patients were 
planned between June 2014 and January 2015. Additional data collection at referring hospitals, 
general practitioners and pharmacies was concluded by the end of 2015. 
 
Procedure of Follow up 
After written informed consent was provided, patients were invited to an outpatient visit in the hospital 
where they were treated during the PANTER trial. If patients were unable to attend, the coordinating 
investigator (RAH) visited patients at home. During visits, recorded medical history during follow-up 
years was verified, with special attention to hospital re-admittance (in particular in hospitals other than 
in which the patient was initially treated), endoscopic or surgical interventions, gastrointestinal 
complaints, pain and medication (i.e. pancreatic enzymes, oral antidiabetics and insulin). Before the 
follow-up visit, patients received validated quality of life questionnaires (EQ-5D9 and SF-3610) to fill out 
at home. Physical examination was performed with special attention to the abdomen. Stool samples 
were collected to evaluate exocrine pancreatic function. Medical information of patients who died 
during follow up was collected from hospital records and through contact with general physicians and 
contact with relatives. 
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Clinical Outcomes 
In accordance with the PANTER trial, the primary endpoint of the current study was a composite of 
death or major complications; i.e. new-onset multiple organ failure or systemic complications, 
enterocutaneous fistula or perforation of a visceral organ requiring intervention, or intra-abdominal 
bleeding requiring intervention at any time during follow up.4 All the individual components of the 
primary endpoints were assessed by the individual members the original adjudication committee that 
also adjudicated the primary endpoint of the PANTER trial. The committee was blinded for treatment 
assignment. 
Individual components of the primary endpoint were evaluated separately as secondary 
endpoints. Other secondary end-points included pancreatic fistula, incisional hernias, recurrent 
pancreatitis, chronic pancreatitis according to the M-ANNHEIM diagnostic criteria11, endoscopic 
pancreatic intervention, pancreatic surgery, and other related surgical procedures after the index 
admission (i.e. surgical hernia repair, colostomy reversal and cholecystectomy). New onset pancreatic 
endocrine insufficiency was defined as the need for treatment for glycemic control with oral 
antidiabetics or insulin. Pancreatic exocrine insufficiency was measured in a single stool sample using 
Schebo Biotech KIT (Elisa). Exocrine insufficiency was defined as a fecal elastase-1 level of <200 
µg/g feces.12,13 Patient reported medicine use for endocrine or exocrine insufficiency was verified 
through contact with general practitioners and/or pharmacies. 
The clinical outcomes are presented for both the long-term follow-up months (i.e. the months 
following the initial 6 month follow up included in the trial phase analyses) and the overall follow-up 
period (i.e. from index admission to long-term follow up) for easy comparison and correct 
interpretation. 
 
Quality of Life and Pain 
Quality of life scores were obtained by 2 validated questionnaires; the short form 36-item health survey 
(Medical Outcomes Trust, Boston, MA)10 and the EuroQol health status profile.9,14 Both questionnaires 
are implemented in the Dutch health care system by previous translation and validation.15,16 Patients 
filled out both questionnaires at 3, 6 and 12 months after discharge from index (i.e. randomization) 
admission. At long-term follow up, patients received the same questionnaires enabling comparison 
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over time. Results are presented as the physical component and mental component summary 
measures according to US and Dutch standards.10 
In chronic pancreatitis, the Izbicki pain score is a common tool to assess intensity and 
frequency of pain attacks, use of pain medication and restriction from daily activities.17 No such tool is 
available for acute pancreatitis. We therefore used the Izbicki pain score in our follow-up interviews for 
assessment of abdominal pain and impact on daily life.  
 
Cost Analysis 
Utilization of health care resources during the entire follow-up period was evaluated. Variables 
included days of admittance to hospitals (i.e. general ward, intensive care unit), diagnostic procedures, 
therapeutic interventions (i.e. interventional radiology, endoscopy, surgery), outpatient visits/contacts 
(i.e. specialists and nurses), general physician care and use of medication for pancreatic endocrine 
and exocrine insufficiency. A cost analysis from a medical perspective was performed to estimate if 
the difference in costs remained in favor of the minimally invasive step-up group during long-term 
follow up. For prize-calculations we used inflation corrected cost-estimations used during the PANTER 
trial and other trials from our study group. For reference values we consulted cost indicator lists 
provided online by the Dutch Care Authority.18,19 Missing values were calculated manually in 
collaboration with the financial department of the St. Antonius Hospital, Nieuwegein, the Netherlands. 
 
Statistical Analysis 
Analyses were performed according to the principles of intention-to-treat. Outcome measures are 
presented as mean ± standard deviations (SD) or median and interquartile ranges (IQR) as 
appropriate. For statistical significance of continuous variables, the independent sample t-test or 
Mann-Whitney U test were used as appropriate. For categorical data the Chi-square test was used 
and in case of small numbers, the Fisher’s exact test. Cost analyses are presented as mean costs per 
patient per year and mean difference with associated 95% confidence interval (CI). Quality of life 
scores are compared between treatment groups by the independent sample t-test and within treatment 
groups by linear mixed models with unstructured repeated covariance. Data analyses were performed 
using SPSS 22.0 (IBM Corp. Armonk, NY). P-values <0.05 were considered statistically significant. 
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Results 
Follow up and clinical endpoints 
Mean follow up was 86 months (± 11 months) after discharge from the index admission. During the 
PANTER trial, 15 out of 88 included patients died. During the long-term follow-up period another 7 
patients died. Long-term follow up was completed actively (i.e. personal contact, stool sample, quality 
of life questionnaires) in 61 out of 66 surviving patients and passively in 5 surviving and 7 deceased 
patients (i.e. retrospective data collection; Figure 1). Baseline variables were comparable between the 
step-up and open-necrosectomy group during the trial.4 
Clinical end points are given in Table 1. From the index admission to long-term follow up, the 
primary endpoint occurred in 19 (44%) patients assigned to the step-up group and in 33 (73%) 
patients assigned to the open-necrosectomy group (P = 0.005; Table 1, Figure 2). During the long-
term follow up, in the step-up group, 1 patient died after early multiple organ failure during an episode 
of recurrent acute pancreatitis. A further 4 deaths occurred in the step-up group which were unrelated 
to pancreatitis: 1 due to stroke, 1 due to metastatic prostate cancer, 1 due to a ruptured abdominal 
aortic aneurysm and 1 most likely due to cardiac arrest. In the open-necrosectomy group, 1 patient 
died after severe intra-abdominal bleeding after endoscopic transluminal drainage of a residual, 
symptomatic pancreatic fluid collection. A second patient from the open-necrosectomy group died 
following metastatic esophageal cancer. 
 During long-term follow up, five patients had a persistent pancreatic fistula. All 5 patients were 
from the step-up group, of whom 4 patients initially underwent videoscopic assisted retroperitoneal 
debridement. Fistula resolved spontaneously in 1 patient, were treated by ERCP and stenting in 2 
patients and by pancreatic surgery in 2 patients, 7 to 32 months after index intervention. Overall, 34 
patients had an incisional hernia resulting from the initial pancreatic necrosectomy, for which 18 
patients (6 patients from the step-up group) underwent surgical correction at a mean of 25 months 
after primary surgery. 
Endocrine insufficiency developed in 42 patients during the entire period of original and long-
term follow up (Table 1). In 19 patients, this was treated with oral antidiabetics alone, in 9 patients with 
insulin alone and in 14 patients with both oral antidiabetics and insulin. In 3 patients, endocrine 
insufficiency resolved during follow up. Overall, 26 patients used pancreatic enzyme supplements 
(Table 1), of whom 6 discontinued taking these enzymes (2 from the step-up group) during follow up. 
10 
 
 
Survivors at long-term follow up 
At the long-term follow up, 66 patients (30 patients from the step-up group) out of the 88 randomized 
patients (75%) were alive. Outcomes are summarized in Table 2. Fourteen patients (21%) 
experienced recurrent episodes of acute pancreatitis of whom 6 patients developed chronic 
pancreatitis. One other patient, who was not readmitted for recurrent acute pancreatitis also developed 
chronic pancreatitis (total: 7 patients; 11%). Pancreatic endocrine insufficiency was present in 12 
(40%) patients from the step-up group and 23 (64%) patients from the open-necrosectomy group (P = 
0.053). According to the fecal elastase-1 test, exocrine insufficiency was present in 29% and 58% 
respectively (P = 0.03). At long-term follow up, 5 (17%) patients from the step-up group and 14 (39%) 
patients from the open-necrosectomy group used supplemental pancreatic enzymes (P = 0.047), of 
whom 2 and 9 patients respectively had pancreatic exocrine insufficiency according to their fecal 
elastase-1. The test was not performed in 1 patient in each group. 
 Subjective abdominal complaints and Izbicki pain scores are summarized in Table 2. In 8 
patients (4 from each group) with pancreatic exocrine insufficiency and in 16 patients (11 patients from 
the step-up group) without pancreatic exocrine insufficiency, no complaints were reported and no 
supplemental enzymes were used at long-term follow up. Of the 5 patients (all from the step-up group) 
who had complaints of steatorrhea, 1 patient used supplemental pancreatic enzymes and only 1 
(other) patient had a fecal elastase-1 level of less than 200µg/gram. There were no statistically 
significant differences in Izbicki pain scores between treatment groups.  
  
Quality of life 
Quality of life was measured at approximately 3, 6 and 12 months after discharge from index 
admission and at long-term follow up. Detailed results are given in Supplementary Table 1, including 
the results at long-term follow up, which are also summarized in Table 3. There were no significant 
differences between treatment groups at any of the 4 time-points.  
The SF-36 physical component score (Dutch standard) increased significantly during the first 
year of follow up (step-up: 36 ± 8 at 3 months, to 46 ± 9 at 1 year (P = <0.01); open: 40 ± 12 at 3 
months to 44 ± 13 at 1 year (P = 0.04)), after which it remained stable, as compared with the long-term 
follow up in both treatment groups. The physical component scores at long-term follow up did not 
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reach the general population scores of 50 ± 10. The SF-36 mental component score (Dutch standard) 
increased slightly during follow up in both treatment groups. At long-term follow up, the SF-36 mental 
scores (step-up: 47 ± 11; open: 48 ± 11) approximated the general population scores of 50 ± 10.10 
The EQ-5D scores significantly increased during the entire follow up in the step-up group (0.64 
± 0.26 at 3 months to 0.81 ± 0.21 at long-term follow up; P < 0.01). The increase in the open-
necrosectomy group (0.70 ± 0.27 at 3 months to 0.75 ± 0.30 at long-term follow up) was lower and 
was not statistically significant. The perceived health score increased up to 1 year after follow up in the 
step-up group (65 ± 15 at 3 months and 75 ± 17 at 1 year; P = 0.03) and remained stable in the open-
necrosectomy group (70 ± 14 at 3 months and 71 ± 16 at 1 year; P = 0.44), after which it decreased to 
equal values at long-term follow up (70 ± 19 and 69 ± 20 respectively). The increasing slopes over 
time in all quality of life scores did not differ significantly between the step-up group and the open-
necrosectomy group (Supplementary Table 2). Considering all patients at long-term follow up, all 
quality of life scores measured were significantly lower in patients who reported abdominal pain (i.e. 
Izbicki score > 0), as compared with patients who did not report pain (Supplementary Table 3). Quality 
of life scores at the end of follow up did not differ significantly between patients with 1 or more 
subjective abdominal complaints, as compared with patients without abdominal complaints. There was 
also no difference between patients with or without endocrine or exocrine insufficiency (Supplementary 
Tables 4 to 7).  
 
Health care resource utilization 
Invasive pancreatic interventions, surgical procedures directly or indirectly related to necrotizing 
pancreatitis and hospital admission during the study period are presented in Table 4. Pancreatic 
surgery is further specified in Supplementary Table 8. During long-term follow up, 9 patients 
underwent catheter drainage of a residual symptomatic pancreatic fluid collection at a mean of 23 
months after index intervention; 3 patients underwent percutaneous drainage (2 patients from the 
step-up group) and 6 patients underwent endoscopic transluminal drainage (2 patients from the step-
up group). These 9 patients had previously undergone necrosectomy. Among patients who underwent 
catheter drainage of a pancreatic fluid collection or pancreatic surgery during long-term follow up, 8 
patients had (clinical/radiological) signs of (partly) disconnected pancreatic duct due to gland necrosis 
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with a vital remnant tail section. Details on diagnosis and treatment of these patients are provided in 
Supplementary Table 9. 
Costs are presented in Supplementary Table 10. During long-term follow up, the difference in 
overall medical costs between treatment groups was not statistically significant. 
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Discussion 
We studied the clinical outcomes, quality of life and health care utilization in 73 patients during long-
term follow up after randomization to a surgical step-up approach or primary open necrosectomy as 
treatment for necrotizing pancreatitis. Overall, the step-up approach reduced the primary endpoint of 
death or major complications, as compared with primary open necrosectomy. Incisional hernias were 
more frequent in the primary open-necrosectomy group, as was pancreatic exocrine insufficiency. 
Also, there was a trend towards a higher prevalence of pancreatic endocrine insufficiency in the open-
necrosectomy group. During long-term follow up, no differences in rates of pancreatic interventions, 
number of re-admissions, quality of life or medical costs were seen between the two groups. External 
pancreatic fistulas that persisted beyond 6 months after discharge from the index admission were only 
observed in the step-up group.  
All patients assigned to the primary open-necrosectomy group underwent 1 or more 
necrosectomy procedures during the index admission and initial 6 months follow-up period of the trial. 
In the step-up group, 35% of patients undergoing catheter drainage recovered without further 
necrosectomy. In patients treated with catheter drainage only, residual pancreatic necrosis or necrotic 
collections could have become symptomatic, which would have required additional invasive 
interventions beyond the 6 months of follow up as defined in the original protocol of the PANTER trial. 
In the current long-term follow-up study, only 2 of the patients who initially recovered with catheter 
drainage only, underwent additional pancreatic surgery. In total, 4 patients from the step-up group and 
2 patients from the open-necrosectomy group underwent pancreatic surgery during long-term follow 
up. In general, the need for additional surgery following the initial episode of necrotizing pancreatitis 
was low, and in line with 2 other studies on invasive interventions during long-term follow up after 
necrotizing pancreatitis.20,21 A minimally invasive step-up approach thus appears to be equally 
effective as a primary open necrosectomy in treating sepsis during the primary episode of infected 
necrotizing pancreatitis, without an increased risk of additional radiological or surgical interventions 
during long-term follow up. Moreover, attributed to the minimally invasive approach, there were fewer 
incisional hernias in the step-up group, leading towards a trend in fewer surgical incisional hernia 
repairs. 
Functional endocrine and exocrine impairment of the pancreas following an episode of 
necrotizing pancreatitis has been evaluated in several meta-analyses.22,23 Studies comparing 
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minimally invasive approaches with open necrosectomy, however, focused mainly on short-term, 
clinical end-points and did not perform a long-term follow up with regard to pancreatic function.24-26 Our 
study showed a clear overall lower rate of pancreatic enzyme use in the step-up group. This was 
already apparent at the initial 6 months follow up and did not increase further during subsequent 
years. At long-term follow up, a significantly greater number of patients in the open-necrosectomy 
group had fecal elastase-1 levels below the threshold of 200µg/gram and twice as many used 
supplemental pancreatic enzymes. These findings are new, as fecal elastase testing was not 
performed routinely in the original study. Overall, no difference in the number of patients using 
antidiabetic medication was seen between groups. At long-term follow up, however, there was a trend 
towards a lower incidence of antidiabetic medication use in the step-up group. Altogether, our findings 
suggest that the step-up approach preserves pancreatic parenchyma and function, as compared with 
primary open necrosectomy. The beneficial difference for the step-up approach becomes apparent 
shortly after recovery of the disease and remains constant during the long-term. 
Our study is the first to compare quality of life following two different methods of invasive 
intervention for necrotizing pancreatitis. We found a significant improvement in quality of life in the 
physical state (SF-36 questionnaire) during the first year in both treatment groups, which is in line with 
a previous longitudinal study in 21 patients with necrotizing pancreatitis treated in the intensive care 
unit.27 The generic health score (EQ-5D questionnaire) increased gradually over time in both treatment 
groups, but the increase in the step-up group was more prominent. The step-up group started with a 
lower score at 3 months, which may be attributable to the physical disability because of continued 
percutaneous catheter drainage. Subsequently, a more rapid increase in their physical state was seen 
between 3 and 6 months. However, at none of the measurement time points, the difference between 
the treatment groups was statistically significant. Quality of life at long-term follow up did not differ 
between patients with and without endocrine or exocrine pancreatic insufficiency, which is noteworthy 
as these conditions impose the burden of using daily medication, dietary changes and the 
consciousness of physical illness. As patients get accustomed to the daily adaptations necessary to 
regulate their disease, they apparently perceive a similar quality of life, as compared with patients 
without endocrine or exocrine insufficiency. 
During the initial 6 months follow up of the PANTER trial, the step-up approach reduced costs 
by 12%.4 During long-term follow up there was no difference in overall medical costs per patient per 
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year between the treatment groups in our detailed, medical perspective cost analysis. However, in line 
with the higher prevalence of exocrine insufficiency and the trend towards more endocrine 
insufficiency of survivors at long-term follow up in the open-necrosectomy group, a trend of higher 
annual costs for pancreatic enzyme replacement therapy and antidiabetics per patient in the open-
necrosectomy group was observed. This is particular noteworthy because the worldwide incidence of 
acute pancreatitis and health care costs are increasing.28 
This study is unique as it is the first to describe the long-term follow up of a randomized trial 
comparing two fundamentally different invasive intervention strategies for necrotizing pancreatitis. We 
performed a thorough prospective follow up on clinical end-points, health care utilization and quality of 
life. Nonetheless, a few issues need to be addressed. First, our definition of endocrine insufficiency 
was based on the use of antidiabetic medication instead of a serum glucose test. Although, in the 
Netherlands, patients in the follow up of severe necrotizing pancreatitis are regularly checked on blood 
glucose levels, impaired glucose intolerance without overt signs and symptoms of diabetes in patients 
not using antidiabetics could have been missed. Second, quality of life questionnaires were not 
collected annually after the first year. This resulted in a large gap of approximately 6 years between 
the last 2 measurement moments. In theory, a potential clinically significant difference in quality of life 
between both treatment groups in the intermediate years may have gone by unnoticed. Studies show 
that, as time goes by, patients tend to become accustomed to their physical impairment. As a result, 
quality of life may become comparable between treatment groups at long-term follow up.29 Third, 
although detailed, our long-term cost analysis was limited to the medical perspective and did not 
include visits to paramedics (e.g. physiotherapy), nor loss of productivity and costs and effects for 
relatives. 
The appropriate technical devices for minimally invasive interventions in necrotizing 
pancreatitis have become more widely available and as a result clinical experience has increased 
worldwide. As a consequence, the answer to the question if there still is a place for a primary open 
necrosectomy in necrotizing pancreatitis becomes clearer. Following the randomized PANTER trial our 
group also performed the randomized TENSION trial to compare the endoscopic step-up approach 
with the surgical step-up approach and found no difference in major complications or death.30 A recent 
international study pooled individual patient data of 1980 patients from 15 cohorts undergoing 
necrosectomy for necrotizing pancreatitis and found that minimally invasive necrosectomies (both 
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surgical and endoscopic) reduced in-hospital death in critically ill patients, as compared with open 
necrosectomy.26 These findings are supported by recent large series.25,31 Some advocate that a down-
side of a minimally invasive step-up approach is that patients need additional invasive interventions 
during follow up because of persisting collections or necrosis and that for this reason a primary open 
necrosectomy is a more definitive initial treatment. Results of our current study refute this assumption 
and further accentuate the benefits of a minimally invasive step-up approach during follow up. It 
should be acknowledged, however, that necrotizing pancreatitis is a very heterogeneous disease. 
Different invasive treatment strategies therefore need to be considered in each individual patient, 
without ruling out the option of open necrosectomy. Nevertheless, following from the results of our 
longstanding experience in nationwide research on treatment of necrotizing pancreatitis, we feel 
confident to emphasize the long-term superiority of the minimally invasive step-up approach over 
primary open necrosectomy in the treatment of infected necrotizing pancreatitis. 
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Figure 1 Patient flow chart 
 
 
 
Figure 2 Probabilities of primary endpoint free survival of patients randomized to the step-up approach and primary open necrosectomy. 
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Table 1. Clinical endpoints according to treatment group in 88 patients included in the PANTER trial. 
 Original follow-up period plus long-term follow up New events during long-term follow up 
 
Outcome 
Step-up 
approach 
(N = 43) 
Open 
necrosectomy 
(N = 45) 
Risk Ratio 
(95% CI) 
P 
Step-up 
approach 
(N = 35) 
Open 
necrosectomy 
(N = 38) 
Risk Ratio 
(95% CI) 
P 
Primary composite end point# - 
no. (%) 
19 (44) 33 (73) 
0.60 
(0.41 - 0.88) 
0.005 5 (14) 3 (8) 
1.81 
(0.47 - 7.02) 
0.47* 
Secondary end points – no. (%)         
New onset multiple organ 
failure or systemic 
complications 
6 (14) 19 (42) 
0.33 
(0.15 - 0.75) 
0.003 1 (3) 1 (3) 
1.09 
(0.07 - 16.71) 
1.00* 
Multiple-organ failure 6 (14) 18 (40) 
0.35 
(0.15 - 0.80) 
0.006 1 (3) 0 - 0.48* 
Multiple systemic 
complications 
0 1 (2) - 1.00* 0 0 - - 
Intraabdominal bleeding 
requiring intervention 
7 (16) 12 (27) 
0.61 
(0.27 - 1.40) 
0.24 0 2 (5) - 0.49* 
Enterocutaneous fistula or 
perforation of a visceral 
organ requiring intervention 
6 (14) 10 (22) 
0.63 
(0.25 - 1.58) 
0.32 0 0 - - 
Death 13 (30) 9 (20) 
1.51 
(0.72 - 3.17) 
0.27 5 (14) 2 (5) 
2.71 
(0.56 - 13.1) 
0.25* 
Other outcomes – no. (%)         
Pancreatic fistula  12 (28) 17 (38) 
0.74 
(0.40 - 1.36) 
0.33 0 0 - - 
Incisional hernia† 10 (23) 24 (53) 
0.44 
(0.24 - 0.80) 
0.004 7 / 32 (20)₸ 13 / 26 (50)₸ 
0.44 
(0.20 - 0.93) 
0.03 
New-onset endocrine 
insufficiency¥ 
17 (40) 25 (56) 
0.74 
(0.49 - 1.11) 
0.13 10 / 28 (36)₸ 8 / 21 (38)₸ 
0.94 
(0.45 - 1.96) 
0.61 
New-onset pancreatic 
enzyme use 
7 (16) 19 (42) 
0.39 
(0.18 - 0.82) 
0.006 4 / 32 (13)₸ 4 / 23 (17)₸ 
0.72 
(0.20 - 2.58) 
0.69 
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* The Chi square test was used unless indicated with an *, then the Fisher’s exact test was used due to small numbers. 
# Multiple events in the same patient were considered as 1 end point. 
¶ Mann-Whitney U test when median (range) and t-test for mean ± SD. 
† Missing data: Incisional hernia new during follow-up years; 1 patient (open-necrosectomy group).  
¥ Defined as the use of oral antidiabetic and/ or insulin therapy. 
₸ Patients who already developed an incisional hernia, endocrine insufficiency or exocrine insufficiency at the end of the PANTER trial (i.e. at the start of long-
term follow up) were not included in the analysis. 
§ 2 distal pancreatectomies (indication: fistula, chronic pancreatitis), 1 pancreaticojejunostomy (indication fistula) and 2 marsupializations (indication chronic 
pancreatitis and residual symptomatic pancreatic fluid collection/ cyst). 
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Table 2. Outcome of step-up approach and open necrosectomy of survivors at long-term follow up. 
Outcome 
Step-up approach 
(N = 30) 
Open necrosectomy 
(N = 36) 
P* 
Follow up (months) 85 ± 11 87 ± 11 0.45# 
Recurrent pancreatitis - no. (%)₸ 6 (20) 8 (22) 0.83 
No. pancreatitis episodes per patient - 
median (range)₸ 
3 (1 - 5) 1 (1 - 3) 0.09 
New onset endocrine insufficiency - no. (%)    
Present at follow-up visit 12 (40) 23 (64) 0.053 
Oral medication 8 (67) 20 (87)  
Insulin 5 (42) 14 (61)  
Exocrine insufficiency    
Fecal elastase-1 mean value‡ 283 ± 141 200 ± 150 0.03# 
<200 µg / gram - no. (%)‡ 8 / 28 (29) 18 / 32 (56) 0.03 
Enzyme use at long-term follow up - no. (%) 5 (17) 14 (39) 0.047 
Chronic pancreatitis - no. (%) 3 (10) 4 (11) 0.88 
 
Step-up approach 
(N = 28)† 
Open necrosectomy 
(N = 31)† 
P* 
Abdominal complaints - no. (%)    
Bloating || 8 (29) 2 10 (32) 8 0.76 
Cramps || 9 (32) 3 10 (32) 5 0.99 
Diarrhea || 4 (14) 1 8 (26) 3 0.27 
Steatorrhea || 5 (18) 1 0 - 0.02* 
Izbicki pain score - mean ± SD 21 ± 27 19 ± 25 0.76# 
Patients with pain only N = 14 43 ± 23 N = 14 42 ± 19 0.99# 
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* The Chi square test was used unless indicated with an *, then the Fisher’s exact test was used due to small numbers. 
# Independent sample t-test for mean ± SD; Mann-Whitney U test for median (range). 
₸ Defined by the Atlanta 2012 Classification.32 Additional mild attacks for which patients were not admitted to the hospital are not accounted for. 
‡ Fecal elastase-1 is measured in 60 patients; in 28 (93%) patients in the step-up group and 32 (89%) patients in the open-necrosectomy group. 
Fecal elastase-1 value is measured from 15-500 µg / gram. To patients with fecal elastase test levels of <15 µg / gram a value of 5 µg / gram was 
assigned and to patients with fecal elastase test levels of >500 µg / gram a value of 510 µg / gram was assigned. 
† Izbicki pain score and abdominal complaints are scored for 28 patients in the step-up group and 31 patients in the open-necrosectomy group 
through outpatient visit and/or telephone interviews. 
|| The first column in each treatment group shows the number of patients with the symptom, the second column shows the number of patients who 
also have pancreatic exocrine insufficiency according to their fecal elastase-1 value. Statistical testing was performed on data in the first column. 
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Table 3. Quality of life of 60 patients at long-term follow up after treatment for necrotizing pancreatitis.* 
 
Step-up approach 
(N = 28) 
Open necrosectomy 
(N = 32) 
P 
SF-36 Physical health component  
US standard 43 ± 12 42 ± 11 0.63 
Dutch standard 44 ± 12 43 ± 12 0.70 
SF-36 Mental health component  
US standard 49 ± 11 50 ± 11 0.82 
Dutch standard 47 ± 11 48 ± 11  0.89 
EQ-5D based health utility scores  
US values  0.84 ± 0.17 0.78 ± 0.24 0.29 
Dutch values  0.81 ± 0.21 0.75 ± 0.30 0.33 
Health state score# 70 ± 19 69 ± 20 0.90 
 
* Quality of life was scored for 28 patients in the step-up group and 32 patients in the open-necrosectomy group through validated, patient reported 
questionnaires. The scores on the SF-36 physical and mental health components range from 0 to 100, with higher scores indicating better quality of 
life. Linear transformations were performed to standardize the scores to a mean score of 50 ± 10 in a general US and Dutch population. The utilities 
of the observed health score profiles on the EQ-5D are based on the time trade-off elicitation technique from interviews with adults from the US 
general population and the Dutch general population, respectively.16,33 Utilities range from either -0.109 (US) or - 0.330 (Dutch), indicating serious 
health problems, to 1.0, indicating no problems at all.  
#The Health state scores range from 0 to 100, with higher scores indicating better perceived health. 
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Table 4. Health care resource utilization according to treatment group in 88 patients included in the PANTER trial. 
 Original follow-up period plus long-term follow up New events during long-term follow up 
 
Outcome 
Step-up 
approach 
(N = 43) 
Open 
necrosectomy 
(N = 45) 
Risk Ratio 
(95% CI) 
P 
Step-up 
approach 
(N = 35) 
Open 
necrosectomy 
(N = 38) 
Risk Ratio 
(95% CI) 
P 
Catheter drainage of 
peripancreatic fluid 
collection - no. (%) 
43 (100) 21 (47) - <0.001 4 (11) 5 (13) 
0.87 
(0.25 - 2.98) 
1.00* 
No. of drainage 
procedures 
87 40   5 8   
Necrosectomy of pancreatic 
necrosis - no. (%) 
26 (60) 45 (100) - <0.001 0 0 - - 
Other pancreatic surgery# 4 (11) 2 (5) - - 4 (11) 2 (5) 
2.17 
0.42 - 11.13) 
0.42* 
Incisional hernia repair 6 (17) 12 (32) - - 6 (17) 12 (32) 
0.54 
(0.23 - 1.29) 
0.15 
Ileostomy / colostomy 
reversal 
2 (5) 5 (11) 
0.42 
(0.09 - 2.04) 
0.13 2 (6) 3 (8) 
0.72 
(0.13 - 4.08) 
0.71 
Cholecystectomy 18 (42) 22 (49)  
0.86 
(0.54 - 1.36) 
0.51 9 (26) 8 (21) 
1.22 
(0.53 - 2.81) 
0.64 
Days in hospital - median 
(range) 
72 (1 - 287) 73 (1 - 297) - 0.74 9 (0 - 230) 17 (0 - 113) - 0.42 
Related to necrotizing 
pancreatitis 
- - - - 0 (0 - 112) 8 (0 - 51) - 0.27 
Unrelated to 
necrotizing pancreatitis 
- - - - 3 (0 - 118) 5 (0 - 108) - 0.71 
Days in intensive care unit - 
median (range) 
13 (0 - 281) 11 (0 - 111) - 0.33 0 (0 - 29) 0 (0 - 12) - 0.28 
Related to necrotizing 
pancreatitis 
- - - - 0 (0 - 2) 0 (0 - 9) - 0.78 
Unrelated to 
necrotizing pancreatitis 
- - - - 0 (0 - 29) 0 (0 - 12) - 0.08 
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* The Chi square test was used unless indicated with an *, then the Fisher’s exact test was used due to small numbers. 
# 2 distal pancreatectomies (indication: fistula, chronic pancreatitis), 2 pancreaticojejunostomies (indication fistula) and 2 marsupializations 
(indication chronic pancreatitis and residual symptomatic pancreatic fluid collection / cyst). 
 
